Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies

被引：0
|
作者：
Arnold, Douglas
Cohen, Jeffrey
Barkhof, Frederik
Selmaj, Krzysztof
Margolin, David
Palmer, Jeffrey
Fox, Edward
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E35 / E36
页数：2
相关论文
共 50 条
  • [1] Alemtuzumab improves MRI outcomes in treatment-naive active relapsing-remitting multiple sclerosis patients: three-year follow-up from CARE-MS I
    Arnold, D. L.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Fisher, E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 41 - 41
  • [2] Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II
    Moreau, T.
    Margolin, D. H.
    Kasten, L.
    Singer, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 86 - 86
  • [3] Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II
    Fisher, E.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 113 - 114
  • [4] Durable Effect of Alemtuzumab on Relapse Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis: CARE-MS Three-Year Follow-Up
    Broadley, S. A.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Weiner, H. L.
    Palmer, J.
    Margolin, D. H.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 934 - 935
  • [5] Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up
    Fox, Edward
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Twyman, Cary
    Vladic, Anton
    Margolin, David
    Oyuela, Pedro
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [6] Autoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-Year follow-up of the CARE-MS studies.
    Dayan, C.
    Cuker, A.
    LaGanke, C.
    Fernandez, O.
    Hupperts, R. M. M.
    Sharrack, B.
    Singer, B.
    Vermersch, P.
    Margolin, D. H.
    Chou, E.
    Twyman, C. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 51 - 52
  • [7] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 683 - 683
  • [8] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    JOURNAL OF NEUROLOGY, 2014, 261 : S442 - S443
  • [9] Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up
    Lycke, J.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K. W.
    Weiner, H. L.
    Palmer, J.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 487 - 488
  • [10] Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes
    Krieger, S.
    Freedman, M. S.
    Moreau, T.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 573 - 573
12345